Loading...

Memphasys Limited

MEM.AX•ASX
Healthcare
Biotechnology
A$0.004
A$-0.00(-20.00%)

Memphasys Limited (MEM.AX) Stock Overview

Explore Memphasys Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap7.9M
P/E Ratio-1.22
EPS (TTM)N/A
ROE-0.79%
Fundamental Analysis

AI Price Forecasts

1 Week$0.00
1 Month$0.00
3 Months$0.01
1 Year Target$0.00

MEM.AX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Memphasys Limited (MEM.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 46.47, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.22 and a market capitalization of 7.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

46.47RSI (14)
0.00MACD
16.40ADX
Revenue Growth
290.35%
↑ 290.35%
Profit Growth
A$-0.00
↓ 30.55%
EPS Growth
A$-0.00
↑ 45.71%
Operating Margin
-1111.02%
↓ 44.17%
ROE
-79.09%
↓ 30.55%
Dividend Yield
0.00%
Analyst Recommendations data is not available for MEM.AXAnalyst Recommendations details for MEM.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a central lab human semen analysis from distantly located donors; and AI-Port. An ambient temperature semen transport device used for animal artificial insemination. Memphasys Limited was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. The company was incorporated in 2006 and is based in Homebush, Australia.

CEO

David Ali

Employees

24

Headquarters

30 Richmond Road, Homebush, NSW

Founded

2007

Frequently Asked Questions

;